CB Therapeutics
CB Therapeutics is a Carlsbad, California-based synthetic biology company developing biosynthetic psychedelic compounds and their novel analogues using a proprietary yeast fermentation platform. Founded in 2015, the company has raised $11.62M from investors including Y Combinator, Pioneer Fund, and re.Mind Capital. CB Therapeutics has achieved biosynthesis of psilocybin, psilocin, DMT, and MDMA analogs, holds seven granted patents with twelve pending, and has partnered with atai Life Sciences and Cleveland Clinic for clinical supply. Its PsyVault™ platform houses the largest collection of biosynthetic psychedelics and analogues.
Development Programmes
2Biosynthetic Psilocybin
PsilocybinMental health (TRD / depression) — biosynthetic supply platform
Programme Tracker
Major Depressive Disorder (MDD)
Precision fermentation platform for psilocybin, DMT, and tryptamine analogues. Cleveland Clinic MOU (2020) for clinical trial supply. No clinical trials initiated. No public updates since mid-2020.
Milestones
Discovery completed
CompletedActual: Dec 4, 2019
CB Therapeutics achieved breakthrough biosynthesis of psilocybin, psilocin, and related tryptamines via engineered yeast fermentation
Why it matters: Biosynthetic production of psilocybin via fermentation could dramatically reduce cost vs. chemical synthesis or botanical extraction. CB Therapeutics was among the first companies to demonstrate GMP-viable fermentation routes for psychedelic compounds.
Watch next: GMP manufacturing scale-up, clinical trial supply agreements
Discovery completed
CompletedActual: Jun 3, 2020
Biosynthesis breakthrough for DMT and related tryptamine compounds announced
Why it matters: Expanded the fermentation platform beyond psilocybin to DMT and tryptamine derivatives, broadening potential supply applications.
Licensing deal
CompletedActual: Apr 20, 2020
Collaboration MOU signed with Cleveland Clinic for clinical trial supply of psilocybin, DMT, and MDMA analogues
Why it matters: Cleveland Clinic partnership validated the biosynthetic platform for clinical-grade supply. However, no clinical trials have been publicly registered from this collaboration as of April 2026 — the MOU may be dormant.
Recorded Events
Jun 3, 2020: Discovery completed
Apr 20, 2020: Licensing deal
Dec 4, 2019: Discovery completed
DMT Analogues
DMTDepression / anxiety — biosynthetic DMT analogue library
Quick Facts
- Type
- Private Biotech
- Founded
- 2015
- Lead Stage
- Discovery
- Website
- Visit